Myocardial ischemia-reperfusion (MI/R) injury is a leading cause of morbidity and mortality around the world, characterized by injury to cardiomyocytes that leads to various forms of cell death, including necrosis, apoptosis, autophagy, and ferroptosis. Preventing cell death is crucial for preserving cardiac function after ischemia-reperfusion injury. Ferroptosis, a novel type of cell death, has recently been identified as a key driver of cardiomyocyte death following MI/R. However, the complex regulatory mechanisms involved in ferroptosis remain unclear. Here, we found that SENP2 expression decreased following myocardial ischemia reperfusion injury. Deletion of SENP2 increased cardiomyocyte ferroptosis and hindered cardiac function recovery after MI/R injury, whereas overexpression of SENP2 significantly reduced cardiomyocyte ferroptosis and mitigated MI/R injury. Mechanistically, SENP2 removed the SUMOylation of NCOA4 modified by SUMO1 at K81, K343, and K600 sites. The level of NCOA4 SUMOylation regulated ferritinophagy-dependent ferroptosis through affecting NCOA4 protein stability. SENP2-mediated NCOA4 deSUMOylation alleviated the interaction between NCOA4 and OTUB1, which directly deubiquitinated NCOA4 and maintained its protein stability. Furthermore, administration of SENP2 in the animal MI/R model reduced ferroptosis events, protected the injured myocardium and promoted cardiac function recovery. Collectively, our results demonstrate that SENP2 catalyzes deSUMOylation of NCOA4, alleviates ferritinophagy-mediated ferroptosis in an OTUB1-dependent manner, thereby facilitating cardiac function recovery following MI/R. These findings suggest a potential therapeutic strategy for MI/R treatment.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with limited treatment options and a poor prognosis. Its defining features include rapid proliferation, invasive capacity, and resistance to therapy. Bioinformatics analyses using TCGA and UALCAN datasets were conducted to assess MXRA8 and ELF3 expression and their association with patient survival. The expression levels were validated through qPCR and western blotting. Functional assays, including proliferation, migration, and invasion tests, were performed after silencing or overexpressing MXRA8 and ELF3. Chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays determined ELF3’s role in regulating MXRA8 transcription. An in vivo xenograft model was used to evaluate the effects of ELF3 and MXRA8 on tumor growth. MXRA8 expression was significantly elevated in GBM tissues and associated with reduced overall survival. Functional analyses revealed that MXRA8 knockdown inhibited oncogenic traits. Moreover, ELF3 was overexpressed in GBM tissues and positively correlated with MXRA8 expression. ChIP and dual-luciferase assays confirmed that ELF3 binds to the MXRA8 promoter and activates its transcription. Rescue experiments showed that MXRA8 overexpression could reverse the tumor-suppressive effects of ELF3 knockdown. In vivo, silencing ELF3 or MXRA8 inhibited tumor growth and proliferation. This study suggests that the ELF3-MXRA8 axis may be a critical driver of GBM progression, with ELF3 promoting tumor growth and invasion through transcriptional activation of MXRA8.